EU Endorses Astrazeneca-Daiichi’s Enhertu: A New Hope for Post-Endocrine Breast Cancer Treatment by 2025
European Union Approves Enhertu as Breast Cancer Treatment for Postmenopausal Women The European Medicines Agency (EMA) has made a landmark decision in the fight against breast cancer. On Friday, the EU health regulator endorsed the use of AstraZeneca and Daiichi Sankyo’s drug Enhertu for the treatment of adult patients with HER2-positive breast cancer, who have…